SGLT2i, Hepatic Glucose Production, and SNS

This study investigates how a class of diabetes medications called SGLT2 inhibitors (such as empagliflozin or dapagliflozin) affect how the liver produces glucose and how the nervous system regulates blood sugar. Understanding these effects could improve how we use these medications to treat type 2 diabetes and heart failure. **You may be eligible if...** - You have type 2 diabetes or heart failure being treated with an SGLT2 inhibitor - You are in otherwise stable health - You meet the specific age and health criteria set by the study **You may NOT be eligible if...** - You have type 1 diabetes - You have significant kidney impairment - You have conditions that would make study procedures unsafe - You are unable to attend study visits Talk to your doctor to see if this trial is right for you.